Cargando…
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer
SIMPLE SUMMARY: Breast and lung cancers are the most diagnosed cancers in the United States. Despite advances in treatment, over 176,000 deaths are expected in 2021, highlighting the need for new therapies. We evaluated MSU42011, a new RXR receptor activator, in murine models of breast and lung canc...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508021/ https://www.ncbi.nlm.nih.gov/pubmed/34638488 http://dx.doi.org/10.3390/cancers13195004 |